Search results
Added:
6 months ago
Source:
Radcliffe Cardiology
Adding aspirin to an oral anticoagulant (OAC) regimen results in a higher risk of ischaemic events, all-cause mortality, and major bleeding in patients with chronic coronary syndrome (CCS) at high atherothrombotic risk, according to the results of the AQUATIC trial.¹ The study was stopped early due to an excess of deaths in the aspirin group.The AQUATIC trial was a multicentre, double-blind,…
View more
Added:
11 months ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
Early withdrawal of aspirin in favour of potent P2Y12 inhibitor monotherapy following percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) did not meet the criteria for noninferiority regarding ischaemic events compared to standard dual antiplatelet therapy (DAPT), according to the results of the NEO-MINDSET trial.¹ The strategy did, however, demonstrate superiority in…
View more
Added:
2 years ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111).
In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at…
View more
Added:
3 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) was joined by the TUXEDO-2 Principal Investigator, Dr Sripal Bangalore to present the findings of this late-breaking randomized trial comparing ticagrelor versus prasugrel in patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)…
View more
Individualising Antithrombotic Strategies for ACS and CCS
Added:
1 year ago
Review Article
Shortened Dual Antiplatelet Therapy
Added:
2 years ago
Review Article
Carlo Patrono
Job title: Adjunct Professor of Pharmacology
Author
Added:
2 years ago
AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.Trials discussed in detail include:SELECT: Semaglutide and Cardiovascular Outcomes in Obesity…
View more
Added:
12 months ago
Join renowned interventional cardiologists Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) for an exclusive preview of ACC.25's most significant late-breaking science.This episode of View from the Thoraxcenter delivers authoritative analysis of pivotal cardiovascular trials set to revolutionize clinical practice and research. Elevate your conference…
View more